INDICATION

EVENITY™ is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Read More

available osteoporosis therapy. The anabolic effect of EVENITY™ wanes after 12 monthly doses of therapy. Therefore, the duration of EVENITY™ use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an antiresorptive agent should be considered. Close
home-icon-png

US women over the age of 50 will have an osteoporosis-related fracture in her lifetime1

Women with postmenopausal osteoporosis are at their highest risk for another fracture in the year after their initial fracture2

owm_fracture

*Data represents a population-based study of 4,140 postmenopausal women aged 50-90 years.

Many postmenopausal women with osteoporosis continue to go untreated despite their risk for fracture3

 
owm_women

Only 1 in 6 women receive treatment within 6 months after an osteoporosis-related fracture4

Bone-building agents are indicated for women with high fracture risk,5-7 yet less than 1% of osteoporosis treatment prescriptions are for anabolic therapies8,*

*From January 2018 to January 2019.

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE, AND CARDIOVASCULAR DEATH
EVENITY™ may increase the risk of myocardial infarction, stroke and cardiovascular death. EVENITY™ should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY™ should be discontinued.

Back to Top

References: 1. US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: Department of Health and Human Services, Office of the Surgeon General; 2004. 2. van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. 2009;68:99-102. 3. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25:2359-2381. 4. Boytsov NN, Crawford AG, Hazel-Fernandez LA, et al. Patient and provider characteristics associated with optimal post-fracture osteoporosis management. Am J Med Qual. 2017;32:644-654. 5. EVENITY™ (romosozumab-aqqg) prescribing information, Amgen. 6. Forteo® (teriparatide) prescribing information, Eli Lilly and Company. 7. Tymlos® (abaloparatide) prescribing information, Radius Health, Inc. 8. Data on file, Amgen. 2019.